NasdaqGS:IONSBiotechs
Ionis Pharmaceuticals Q4 Loss Of US$229 Million Tests Bullish Profitability Narrative
Ionis Pharmaceuticals FY 2025 earnings snapshot
Ionis Pharmaceuticals (IONS) closed FY 2025 with fourth quarter revenue of US$203 million and a basic EPS loss of US$1.41, alongside a trailing twelve month revenue base of US$944 million and a TTM basic EPS loss of US$2.38. Over the past year, quarterly revenue has moved between US$131.6 million and US$452.0 million, while basic EPS swung from a profit of US$0.78 in Q2 2025 to losses of US$0.93 in Q1 and US$0.80 in Q3. This sets up a results...